Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T15:10:41.209Z.
Calculation as of: 2026-10-06T15:10:41.209Z.
Quote observation: 2026-10-06T15:10:15.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 3a5f53e60080e4c0bd8028294acadec9828b96594dd07725d589d3e2217ece04
PE RATIO
N/A
Market Cap
$486.12M
PE Ratio
18.50
TTM Avg
12.02
3Y Avg
15.67
5Y Avg
102.65
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | $505.65M | N/A | N/A | N/A | N/A |
| Oculis Holding AG (OCS)vs › | $495.09M | N/A | N/A | N/A | N/A |
| 908 Devices Inc. (MASS)vs › | $517.35M | N/A | 12.07 | 12.07 | 12.07 |
| Monopar Therapeutics Inc. (MNPR)vs › | $520.65M | N/A | N/A | N/A | N/A |
| Evolus, Inc. (EOLS)vs › | $488.92M | N/A | N/A | N/A | N/A |
| Altimmune, Inc. (ALT)vs › | $523.14M | N/A | 0.20 | 0.20 | 0.20 |
| Puma Biotechnology, Inc. (PBYI)vs › | $486.12M | 18.50 | 12.02 | 15.67 | 102.65 |
| Bright Minds Biosciences Inc. (DRUG)vs › | $478.35M | N/A | N/A | N/A | N/A |
| Arvinas, Inc. (ARVN)vs › | $477.46M | 46.25 | 54.09 | 54.09 | 54.09 |
| Phathom Pharmaceuticals, Inc. (PHAT)vs › | $534.31M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$1.47
Forward EPS (Est.)
$-0.60
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
